Peptide KPV OXY-KPV (5 mg) OxyPharma

Catalogue entry: Peptide KPV OXY-KPV (5 mg) OxyPharma. Labelled content: 5 mg. Listed pack: 1 vial. The amount identifies labelled product content, not an administration dose.

Identity and mechanism

KPV is the lysine-proline-valine tripeptide associated with the C-terminal sequence of alpha-melanocyte-stimulating hormone. Its research focuses on inflammatory signalling and epithelial transport. A short sequence name does not establish the formulation, stability or exposure of a supplied product.

What the research measured

Dalmasso and colleagues reported PepT1-mediated uptake and anti-inflammatory findings in Gastroenterology in 2008. Kannengiesser and colleagues also studied KPV in mouse colitis models. Later nanoparticle experiments examined delivery approaches. These findings are tied to cell systems, animal disease models or specific delivery technologies; they cannot be transferred automatically to an unrelated vial.

Sporting claims and limitations

In sporting discussions, gut comfort and reduced inflammation are often linked to better recovery. That chain of claims requires human outcome evidence, not only an inflammatory marker. BPC-157 addresses a different research literature, while thymosin alpha-1 concerns another peptide and immune context. Neither supplies the missing clinical evidence for KPV or for combining these materials.

Product identity and documentation

For this article, the selected quantity is the labelled content rather than an administration instruction. Useful documentation identifies the exact tripeptide, chemical form and actual batch, with analytical methods suitable for the preparation. Purity, formulation quality and suitability for human use are separate questions. Limited human safety information should remain visible rather than being hidden behind the short sequence or a general anti-inflammatory description.